Genomics
A real RNA-medicine platform finally turning into a P&L — but the stock is a pelacarsen option with seven launches as the floor. Own the platform, size for the binary.
Research
The verdict
A real RNA-medicine platform finally turning into a P&L — but the stock is a pelacarsen option with seven launches as the floor. Own the platform, size for the binary.
Ionis invented the antisense-oligonucleotide (ASO) drug class and has spent 36 years (founded Jan 1989, as Isis) turning RNA-targeting chemistry into approved medicines. The plain-terms model: design a short modified-nucleotide strand that binds a specific disease-causing RNA and either degrades it (RNase-H mechanism), blocks it, or re-splices it. After three decades as a royalty-and-milestone licensing engine that handed commercialization to partners, the company flipped in late 2024 into a fully integrated commercial-stage biotech — it now sells drugs itself.
Two revenue engines run side by side:
Seven marketed medicines total: TRYNGOLZA, DAWNZERA, WAINUA, SPINRAZA, QALSODY, TEGSEDI, WAYLIVRA . Two more independent launches teed up for 2026: **olezarsen in severe hypertriglyceridemia (sHTG)** (PDUFA **June 30, 2026**) and **zilganersen in Alexander disease** (NDA submitted Jan 2026, launch H2 2026) .
Customers/payers: US patients via Medicare/Medicaid/commercial payers; partners (AZ, Biogen, Novartis, GSK, Roche, Otsuka, Ono, Sobi, PTC, Theratechnologies) are simultaneously customers (they pay milestones/royalties) and distribution. Suppliers: CDMOs for drug substance/product (oligonucleotide API + finished goods); Ionis runs its own Carlsbad manufacturing plus contract manufacturing. Contract structure: R&D revenue is lumpy and milestone-driven (e.g. a $280M Ono upfront in Q2-2025 single-handedly lifted FY revenue) ``; product sales and royalties are the recurring base.
FY2025 revenue $943.7M, up 34% YoY from $705.1M . Cumulative revenue since inception ~$8.9B (≈$9.1B through Q1-2026) .
Named map, upstream → end-customer:
. Inventories are tiny ($10.0M at YE2025) — pre-launch inventory was historically expensed through R&D, so cost-of-sales understates true unit economics until pre-launch stock is exhausted (management flags this explicitly) ``.Chokepoints: (1) oligonucleotide API capacity — building, but a real bottleneck as multiple launches scale simultaneously; (2) CDMO reliance for finished product; (3) the build-out of an independent commercial infrastructure (salesforce, market access) is itself the scarce internal "input" the 10-K's #1 risk factor centers on ``.
The moat is the platform, the chemistry IP, and 36 years of target/clinical know-how — not any single drug.
. But IP is actively defended — Ionis sued **Arrowhead** (Sept 2025) over plozasiran's apoC-III mechanism (US patent 9,593,333); Arrowhead countersued for invalidity . A loss there would weaken the apoC-III franchise wall.Moat verdict: real and platform-grade, but every individual asset faces a named competitor (see Lens 13), and the new independent-commercial muscle is unproven.
Ionis reports as a single operating segment ("Ionis operations") — the CEO/CODM manages on a consolidated basis ``. So there is no GAAP product-segment EBIT split; the meaningful breakdown is revenue by type and by product, which the filings give precisely:
FY2025 revenue mix (in $M) ``:
| Line | FY2025 | FY2024 | YoY |
|---|---|---|---|
| TRYNGOLZA product sales, net | 107.5 | 0 | new |
| DAWNZERA product sales, net | 7.8 | 0 | new |
| Total product sales, net | 115.3 | 0 | new |
| SPINRAZA royalties | 212.3 | 216.1 | −2% |
| WAINUA royalties | 49.1 | 20.2 | +143% |
| Other royalties | 24.1 | 21.0 | +15% |
| Total royalty revenue | 285.5 | 257.3 | +11% |
| Other commercial revenue | 35.0 | 35.8 | −2% |
| Total commercial revenue | 435.8 | 293.1 | +49% |
| Collaborative agreement (R&D) revenue | 465.8 | 332.6 | +40% |
| WAINUA joint development revenue | 42.1 | 79.4 | −47% |
| Total R&D revenue | 507.9 | 412.0 | +23% |
| Total revenue | 943.7 | 705.1 | +34% |
Trend / cause: the mix is shifting from royalties to own-product, which is the whole thesis. Commercial revenue +49% driven entirely by the TRYNGOLZA launch. SPINRAZA — historically the crown jewel — is flat-to-declining ($212.3M, −2%), the structural worry (Lens 13). R&D revenue is lumpy — FY2025 was flattered by the $280M Ono sapablursen upfront ``; do not extrapolate it as recurring.
Q1-2026 acceleration ``: total revenue $246.1M (+87% YoY vs $131.6M). Product sales $43.0M (TRYNGOLZA $27.1M + DAWNZERA $15.9M, vs $6.3M PY). R&D revenue $138.3M (+149%), juiced by milestones: Roche $50M (AD Phase-1 start, 20% of total revenue), GSK $30M (bepirovirsen EMA/MHLW acceptances, 12%), Otsuka $15M (DAWNZERA EU approval). Royalty revenue dipped to $58.3M (SPINRAZA $43.7M, down from $48.0M) — again the SPINRAZA erosion signal.
Geography: US-centric for own-products; ex-US via partners. No clean geographic revenue table (single-segment reporting). ~$9.1B cumulative revenue since inception through Q1-2026 ``.
The most recent print was a clear beat and an inflection:
; +87% YoY .. **This is a presentation artifact, not a cash crisis:** Q1 reported "operating cash used" of $(792.8)M is distorted by a **$632.5M escrow deposit** set aside to retire the 0% Notes due 2026 (paid April 2026); $200M of that was returned in Q2 . Underlying operating burn is in line with the ~$60–70M/quarter run-rate. A $23.4M unrealized gain flowed through the P&L when a private investee IPO'd (fair value $55.8M, locked till Jan 2027) ``.No transcripts in the research layer (transcripts=0); sentiment is read from labeled web + the filings' own forward language.
Management's framing has shifted hard from "a platform that licenses drugs" to "a commercial company that launches them." The recurring 2025→2026 phrases: "fully integrated commercial-stage," "four independent launches in three years," "accelerating value," "substantial value creation in 2026 with two new independent launches and several pivotal data readouts" . The tone is confident and execution-focused; the new vocabulary is **peak-sales guidance** (olezarsen >$3B) and **cash-flow breakeven 2028** — both signals of a team trying to re-anchor the multiple on a P&L, not a pipeline .
What they've stopped leaning on: pure "number of programs in the pipeline" boilerplate. What they now repeat: launch metrics (HCP demand, payer research) and the catalyst calendar. Sentiment trend: steadily more bullish and more specific across the last ~4 quarters — appropriate given the beats, but it raises the bar.
Provenance-critical lens. Where a multiple isn't cleanly sourced, it's marked n/a rather than fabricated.
| Company | Ticker | Mkt cap | EV | EV/Sales | P/E | Div yield | 5-yr avg ROE |
|---|---|---|---|---|---|---|---|
| Ionis | IONS | ~$12.3B `` | ~$5.49B `` — see conflict | n/a (loss-making; EV figure stale, see note) | −35.4 (negative; loss-making) `` | 0% | negative (accumulated deficit $2.6B) |
| Alnylam | ALNY | ~$39.7B `` | — | ~7× EV/NTM-sales `` | n/a | 0% | n/a |
| Arrowhead | ARWR | — | ~$2.48B `` | n/a | n/a (loss-making) | 0% | negative |
| BridgeBio | BBIO | — | — | n/a | n/a | 0% | n/a |
Read: classic biotech comp problem — IONS and most peers are loss-making, so earnings multiples are meaningless (IONS P/E −35×). The honest relative-value frame is EV/sales and EV/peak-sales-potential. Alnylam (profitable, $4.29B revenue, ~7× EV/NTM-sales ) is the "graduated" RNA comp — the bull case is that Ionis follows the same arc (platform → multiple approved products → profitability → re-rating). Bernstein explicitly argues **IONS and ALNY "should trade together"** . Arrowhead (EV ~$2.48B) is the smaller, earlier siRNA peer and the apoC-III litigation adversary.
Pattern over the last ~2 years (mostly ``):
What it reveals: IONS reacts to binary clinical/regulatory events and launch-trajectory proof, not to quarterly EPS (it's loss-making, so EPS is noise). The dominant single sensitivity is pelacarsen — a positive Lp(a)HORIZON readout opens a multi-billion-dollar royalty stream from a brand-new cardiovascular drug class; a negative one removes the largest call-option leg.
. Lifted olezarsen peak-sales guidance 3× (>$1B→>$3B) and is hitting the launch metrics behind it .. Institutions own ~60–70% of the float . Read: low insider ownership is a mild governance negative but not unusual; the 10b5-1 sales are scheduled/diversification, not a red flag on their own — though they're worth monitoring around the pelacarsen readout.. They manage the convertible stack actively (issued $770M 0% Notes due 2030, retired the 0% 2026s) . Share count has crept from 142M (2022) → 163M (YE2025) → 164.9M (Q1-2026 wtd) via equity raises ($489M public offering 2024) and SBC ``. ROE is negative (accumulated deficit $2.6B) — they have never sustainably earned their cost of capital, the central "will the platform ever pay off" question.Acting as a forensic analyst against the income statement, balance sheet, and cash-flow statement:
. The lumpiness is real and partly discretionary in *timing*: e.g. $280M Ono upfront (Q2-2025) and $95M of Q1-2026 milestones (Roche $50M, GSK $30M, Otsuka $15M) were each recognized **in full, immediately**, because "no remaining performance obligations" . That's defensible accounting but it means headline revenue growth is flattered by one-offs — strip milestones to see the recurring trend.. Underlying burn is normal. Several non-cash royalty/interest items (sale-of-future-royalties: $52.5M non-cash royalty revenue + $72.7M non-cash interest in FY2025) move reported revenue and interest expense without cash — understand the Royalty Pharma accounting before trusting GAAP revenue at face value .Regulatory findings (required sub-section):
. This is offensive IP enforcement (a moat-defense signal), but an adverse ruling would dent the apoC-III franchise. Otherwise only ordinary-course matters .Ionis is loss-making, so the EPS projection is a loss-narrowing path, and the rNPV of the pipeline is the more honest valuation anchor. All outputs `` with arithmetic; inputs labeled.
Anchor actuals : FY2025 revenue $943.7M, net loss $(381.4)M, EPS −$2.38, ~163M shares. Q1-2026 EPS −$0.56. FY2026 revenue guide $875–900M (lower than FY2025 only because of the $280M Ono one-off). Cash-flow breakeven target 2028 ``.
Three-year EPS path (FY2026E–FY2028E):
Bull path: pelacarsen positive + olezarsen-sHTG launch beats ($3B peak trajectory) + ATTR-CM (eplontersen) readout positive → breakeven pulled into 2027, EPS positive 2028. Bear path: pelacarsen fails/delays again + SPINRAZA erodes faster + launches disappoint → breakeven slips past 2028, continued $1.50+ annual losses, another raise.
rNPV cross-check (the real anchor for a catalyst stock): Ionis's ~$12.3B market cap implies the market is paying for the pipeline, not the P&L. The biggest single rNPV swing factor is pelacarsen: an Lp(a) CV-outcomes win addresses >8M patients with elevated Lp(a) + CVD at mid-teens-to-low-20% royalties to Ionis — plausibly a **$1–3B+ peak royalty stream**, partly pre-sold to Royalty Pharma. Olezarsen-sHTG alone carries >$3B peak-sales guidance (wholly owned) ``. The asset stack — 7 marketed + 9 Phase-3 + pelacarsen/eplontersen/bepirovirsen big-indication readouts — is what a buyer of IONS owns.
Brier forecast (NOT logged —
--watchlistrule says skipforecast.ts create). If logged later, the scoreable line that matters is binary, not EPS: "Lp(a)HORIZON pelacarsen primary CV endpoint met (positive topline), resolves by 2026-12-31" — that single readout dominates the rNPV. A secondary line: "IONS FY2028 non-GAAP EPS ≥ $0.00 (reaches breakeven)."
Bull case. Ionis is the original RNA-medicine platform finally compounding into a real P&L. The setup is unusually clean: (1) a launch wave — TRYNGOLZA + DAWNZERA live and beating, olezarsen-sHTG (PDUFA Jun 30 2026, >$3B peak) + zilganersen (H2-2026) imminent — four self-commercialized launches in three years, each carrying full economics instead of a royalty; (2) a partnered call-option stack that costs Ionis nothing to carry — pelacarsen (Novartis, first-ever Lp(a) CV drug, >8M-patient TAM), eplontersen/WAINUA in ATTR-CM (AZ), bepirovirsen hep-B functional cure (GSK, B-Well Phase-3 hit Jan 2026); (3) a platform that keeps minting partnerships (Roche AD, Ono, Otsuka) and next-gen chemistry (MsPA, Bicycle, Vect-Horus, Metagenomi gene-editing) that extends the runway to new tissues; (4) a credible path to 2028 breakeven with $1.9B liquidity to get there. If pelacarsen hits, IONS re-rates toward the Alnylam arc (Bernstein: "should trade together") and the >$3B olezarsen number alone supports the cap. Contrarian read the market is underweighting: the independent-commercial transition is succeeding (Q1 product sales +580% YoY), de-risking the "can a licensing company learn to sell?" question that has capped the multiple for years.
Bear case (2–3 permanent-impairment risks). (1) Pelacarsen is the whole option and it's binary — it already slipped once (H1-2025→H1-2026 on too-few CV events), and Lp(a)-lowering has never been proven to cut CV events. A negative Lp(a)HORIZON guts the single largest value leg and would re-rate the stock down hard. (2) SPINRAZA — still the biggest royalty line ($212M, flat-to-declining) — erodes structurally against Zolgensma (gene therapy) and risdiplam/Evrysdi (oral), and Ionis already pre-sold a slice to Royalty Pharma, so the downside is unhedged while the upside is capped. (3) The independent launches could disappoint on price/access, exactly as US MFN-pricing (CMS GLOBE/GUARD/GENEROUS), 340B, and PBM pressure intensify — a rare-disease pricing model is most exposed precisely when it's scaling. Pre-mortem (18 months out, thesis broke): pelacarsen reads out flat or is delayed again; olezarsen-sHTG launches into a slower-than-modeled payer build and faces Arrowhead's plozasiran head-to-head; SG&A stays elevated; breakeven slips to 2029; the stock round-trips its 2025–26 double. Is the multiple too high? On a P&L basis there is no multiple (loss-making); on rNPV the stock already prices a good pelacarsen outcome — so the risk is asymmetric down into the readout.
Dismantling the bull case:
; Ionis is *suing* Arrowhead, which tells you it feels the threat. HAE: **oral competitors** (DAWNZERA is an injectable in a market moving oral). ATTR: WAINUA enters a **crowded 4-way market** (Pfizer tafamidis, BridgeBio Attruby/acoramidis ramping at **$180M/quarter +24%**, Alnylam Amvuttra/vutrisiran) where eplontersen is a **late entrant** awaiting CARDIO-TTRansform (2026) . SMA: gene therapy + risdiplam already eroding SPINRAZA.Not a stock anymore — a closed M&A. Lilly bought the whole company for $10.50/share cash (closed Jul 2025); the only live "position" is the $3.00 CVR, which pays only if VERVE-102 reaches a US Phase 3 dosing — market priced ~21% odds, a coin-flip dressed as a lottery ticket.
A founder-led rare-disease engine with real ($673M) revenue and a pioneer at the helm — but it just lost its biggest pipeline bet (setrusumab) and is burning ~$466M/yr against ~$534M cash, so the entire equity now rides on two H2-2026 FDA approvals (UX111 Sep 19, DTX401 Aug 23) closing the gap to a promised 2027 profit. Binary, not compounding.
The toll-road of science — a fortress compounder you buy for the next decade, not the next quarter; at ~18x forward EPS it is as cheap as it has been in years precisely because organic growth is stuck at ~2% and the GAAP/adjusted gap is widening, so the bet is that PPI productivity + biopharma normalization + Clario/Olink revenue synergies re-accelerate organic to mid-single-digits before the multiple has to.